The purchase in cash and stock of Grail, a developer of a long-sought blood test that promises to detect cancer early, will be Illumina’s biggest acquisition.
CAMEROON MAGAZINE - GM21/09/20201 Mins read
Illumina Inc., a leading maker of the machines that sequence genes, said Monday it will pay $7.1 billion in cash and stock for a developer of a long-sought blood test that promises to detect cancer early.
The deal for the part of Grail Inc. that Illumina doesn’t already own will move the company deeper into the application of its gene-sequencing technology to the diagnosis and treatment of patients, a potential multibillion-dollar market.
Keywords: Massive parallel sequencing,Research,Forecasting,Massive parallel sequencing, Research, Forecasting,,,
Illumina a déclaré avoir conclu l'acquisition de 7,1 milliards de dollars de...
The market for molecular diagnostics based on hybridization is expected to see...
Associated Title : – detector range realizing the full potential of NextSeq...
